BioSpace News Archive

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces the presentation of 7 clinical posters and presentations at the Symposium of Wound Care Fall 2021, held from October 29 – 31, 2021 in Las Vegas, Nevada.

ViewRay, Inc. announced that the results of a multi-center study of 148 inoperable pancreatic cancer patients treated with MRIdian SMART were presented as part of the Annual Meeting of the American Society for Radiation Oncology, the world’s largest radiation oncology society, held October 24-27, 2021 in Chicago.

Immunic, Inc. announced that the final patient has been enrolled and randomized in its phase 2 CALDOSE-1 trial of lead asset, IMU-838, the company’s selective oral DHODH inhibitor, in patients with moderate-to-severe ulcerative colitis.

Teleflex Incorporated announced financial results for the third quarter ended September 26, 2021.

Merck, known as MSD outside the United States and Canada, announced financial results for the third quarter of 2021.

BD announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Authority, part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response to support the development of a range of COVID-19 combination diagnostic tests for core laboratories, hospitals and at the point of care.

Genocea Biosciences, Inc. today provided a business update for the third quarter ended September 30, 2021.

HCW Biologics Inc. today announced that it has been cleared by the U.S. Food and Drug Administration (FDA) to proceed to evaluate its lead drug candidate, HCW9218, in a first-in-human Phase 1b clinical trial in patients with advanced pancreatic cancer.

Visby Medical™, a leading medical diagnostic company, announced Thomas Prescott, former president and chief executive officer of Align Technology and Cardiac Pathways, will join as the company’s new chairman of the board.

PaxMedica, Inc. today announced that it has presented additional data and analyses from its Phase 2 clinical trial evaluating PAX-101